ADC Therapeutics posts early Phase II lymphoma data for Zynlonta as revenue drops 5.8 percent
ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.